HC Wainwright Research Analysts Boost Earnings Estimates for Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Analysts at HC Wainwright raised their Q2 2024 earnings per share estimates for shares of Celldex Therapeutics in a research note issued on Tuesday, May 7th. HC Wainwright analyst J. Pantginis now anticipates that the biopharmaceutical company will earn ($0.59) per share for the quarter, up from their previous estimate of ($0.67). HC Wainwright currently has a “Buy” rating and a $80.00 target price on the stock. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.85) per share. HC Wainwright also issued estimates for Celldex Therapeutics’ Q3 2024 earnings at ($0.60) EPS, Q4 2024 earnings at ($0.60) EPS, FY2024 earnings at ($2.34) EPS and FY2025 earnings at ($2.67) EPS.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.57) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.19. The business had revenue of $4.13 million during the quarter, compared to analyst estimates of $1.20 million. Celldex Therapeutics had a negative return on equity of 41.06% and a negative net margin of 2,054.46%.

Several other research firms have also issued reports on CLDX. Guggenheim lifted their target price on shares of Celldex Therapeutics from $72.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research report on Friday, March 22nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $66.00.

Celldex Therapeutics Price Performance

Shares of NASDAQ CLDX opened at $41.06 on Thursday. The stock has a market cap of $2.30 billion, a P/E ratio of -14.11 and a beta of 1.60. Celldex Therapeutics has a 1 year low of $22.11 and a 1 year high of $53.18. The firm has a 50-day moving average of $41.57 and a 200 day moving average of $37.05.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC increased its position in shares of Celldex Therapeutics by 70.9% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,941 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 805 shares in the last quarter. Strs Ohio boosted its stake in Celldex Therapeutics by 92.9% during the 4th quarter. Strs Ohio now owns 2,700 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 1,300 shares during the last quarter. Headlands Technologies LLC purchased a new stake in Celldex Therapeutics during the 1st quarter valued at $147,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Celldex Therapeutics by 36.1% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,582 shares of the biopharmaceutical company’s stock worth $181,000 after purchasing an additional 1,746 shares in the last quarter. Finally, Aigen Investment Management LP purchased a new position in shares of Celldex Therapeutics in the fourth quarter worth $251,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.